Colonics
About Me
Recent Posts
- 'Personality Genes' May Help Account For Longevity
- 4 Mushroom Poisonings In 2 Weeks - Doctors Test Milk Thistle As Treatment
- Improved Diagnostics For Sleeping Sickness
- Prostate Growth May Be Slowed By Statins
- New Tools For Psychological Science Research - Facebook And Smartphones
Menu
Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | |||
Friends
Links
Entry 1 of 2381
Last Page | Next Page
6/29/2010
-
Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared To Placebo In People With Type 2 Diabetes
|
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically consequential and sustained reductions in blood sugar as gauged by hemoglobin A1c (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose (PPG).(1,2) Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 (DPP-4) inhibitor as an oral once-daily tablet, as monotherapy and union therapy, to treat type 2 diabetes. The linagliptin data were presented at the 70th Annual stars and bars stars and stripes insulin-dependent insulin-dependent diabetes mellitus mellitus band (ADA) Scientific Sessions in Orlando, Fla...
More: - Read the rest here |
Post A Comment! :: Send to a Friend! |
Share and enjoy
